BDTX Stock Analysis: Buy, Sell, or Hold?
BDTX - Black Diamond Therapeutics, Inc. Common Stock
$2.58
-0.17 (-6.19%)
▼
5d:
-12.25%
30d:
-15.69%
90d:
+15.69%
WAIT
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Smart Money Accumulation
BDTX is down 8.0% this week, but smart money is accumulating calls. Top strike: $2.5 2026-06-18 with 13,937 OI. Call ratio: 99% View Scanner →
Strength: 8.9/10
Get Alerted When BDTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BDTX is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BDTX is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BDTX is currently trading at $2.58, which is considered oversold relative to its 30-day fair value range of $2.64 to $3.03.
Technical Outlook: Technically, BDTX is in a uptrend. Immediate support is located at $2.43, while resistance sits at $3.18. Short-term momentum is weak, with the stock down 6.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.86 (+258.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BDTX is in a uptrend. Immediate support is located at $2.43, while resistance sits at $3.18. Short-term momentum is weak, with the stock down 6.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.86 (+258.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.64 -
$3.03
Company Quality Score
51/100
(HOLD)
Options IV Signal
7th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
82.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 7th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.2%)
- BULLISH: Trading 258.4% below Wall St target ($9.86)
- WARNING: Recommendation downgraded due to -12.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.64 -
$3.03
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.23
(9.0%)
Support & Resistance Levels
Support Level
$2.43
Resistance Level
$3.18
Current Trend
Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.52
Wall Street Target
$9.86
(+258.4%)
Profit Margin
31.9%
Share & Embed Analysis
Last updated: May 18, 2026 2:24 PM ET
Data refreshes hourly during market hours. Next update: 3:24 PM
Data refreshes hourly during market hours. Next update: 3:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BDTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 51 HOLD |
